The Oncology Institute, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Daniel Virnich
- Full Time Employees
- 641
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- 18000 Studebaker Road Cerritos CA United States of America 90703
- IPO Date
- Jun 4, 2020
- CIK
- 0001799191
- Website
- theoncologyinstitute.com
- Similar Companies
- Business
- The Oncology Institute, Inc. operates as a leading value-based community oncology care provider in the United States, specializing in comprehensive cancer treatment services. The company’s core offerings include medical oncology, providing chemotherapy, immunotherapy, targeted therapy, and hormonal therapy tailored to individual patient needs; radiation oncology, delivering advanced external beam radiation therapy, brachytherapy, and stereotactic radiosurgery; and clinical trial integration through strategic partnerships aimed at expanding patient access to cutting-edge therapies. Additionally, The Oncology Institute provides pharmacy services with specialty drug delivery, including Part B drugs, supporting its broad oncology network. Founded in 2007 and headquartered in Cerritos, California, The Oncology Institute serves over 1.8 million patients through an expansive network of clinics focused on high-quality, value-based cancer care. Recent major developments include an expansion of its strategic partnership with Helios Clinical Research to enhance clinical trial access and execution across community oncology settings, reflecting a commitment to integrating research into routine care and advancing health equity. The company reported robust revenue growth in 2025, raising full-year guidance to $495 million to $505 million, with forecasted adjusted EBITDA breakeven by Q4 2025 and positive adjusted EBITDA expected in 2026. Operational expansions include growth of its management service organization network in Florida, opening a dedicated pharmacy location there, and ongoing efforts in AI integration for business office functions to drive efficiency. Financially, The Oncology Institute completed a $16.5 million private placement in early 2025 to support organic growth and working capital. The company also announced new value-based contracts and network expansions in multiple states including Florida and Oregon. Senior leadership changes and board member resignations were noted in late 2025, with active recruitment of expertise to complement the governance team. Overall, The Oncology Institute continues to position itself as a leading community oncology services company by combining clinical care, research partnerships, pharmacy operations, and technology-enabled management services across the U.S. cancer care market.
Oncology Institute Q2 Earnings Call Highlights
The Oncology Institute Rebrands as Starling Oncology
The Oncology Institute Announces Second Quarter 2026 Earnings Release Date and Conference Call
Best Cheap Stocks Under $10 to Buy Now in July
The Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving Liquidity
2 More Stocks to Buy for the AI Convergence
The Oncology Institute (TOI) Soars 5.3%: Is Further Upside Left in the Stock?
3 Stocks to Buy for the AI Convergence
How Much Upside is Left in The Oncology Institute (TOI)? Wall Street Analysts Think 38.07%
Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday
Topicus.com Inc. Announces a Revised Proposal to Acquire ReadyTech
The Oncology Institute Chief Medical Officer to Speak on Value-Based Specialty Care at APG Spring Conference
Topicus.com Inc. (TOI:CA) Shareholder/Analyst Call Prepared Remarks Transcript
The Oncology Institute to Participate in B. Riley Securities Institutional Investor Conference
Constellation Software Inc., Topicus.com Inc. and Lumine Group Inc. Announce Update to Schedule for Annual Meetings
Oncology Institute Q1 Earnings Call Highlights
The Oncology Institute, Inc. (TOI) Reports Q1 Loss, Beats Revenue Estimates
The Oncology Institute Reports First Quarter 2026 Financial Results
Constellation Software Inc. and Topicus.Com Inc. Announce Results for Topicus.com Inc. for the First Quarter Ended March 31, 2026
The Oncology Institute Announces First Quarter 2026 Earnings Release Date and Conference Call